A top-10 global pharmaceutical company had multiple drugs in their Immunology Business Unit indicated for both acute and prophylactic treatments, including the market-leading therapy with $1B+ in annual revenue. They needed to better understand the impact of new entrants across the complete product portfolio.

Viscadia was asked to design, build and deploy forecasting platforms that addressed the end-to-end forecasting needs of the full portfolio, including short-term evaluations, long-range planning, market forecasting and patient analytics.